Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plexxikon Inc.

Division of Daiichi Sankyo Co. Ltd.
www.plexxikon.com

Latest From Plexxikon Inc.

Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions

Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.

Research & Development Companies

Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity

Daiichi Sankyo is to continue with a multinational Phase III trial for its novel candidate for tenosynovial giant cell tumor despite cases of liver toxicity, but has stopped enrolment short of target and modified the protocol.

Cancer Safety

Daiichi Sankyo Hoping Its Post-Olmesartan Plan Comes Together

"I love it when a plan comes together," Hannibal Smith of TV show The A-Team used to say, a catchphrase which Daiichi Sankyo will be hoping is appropriate in around five years' time as it looks back on the results of its new mid-term strategy.

BioPharmaceutical Japan

Will Genentech's Cotellic Survive Alternative Pricing Demands?

Genentech Inc.'s and Exelixis Inc.'s Cotellic (cobimetinib), a MEK inhibitor, made it across the FDA's finish line on Nov. 10, but now the firms must confront the ultimate test of the drug's success – selling it, which is increasingly becoming more difficult in a climate where payers are becoming more and more demanding about using alternative pricing arrangements.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Daiichi Sankyo Co. Ltd.
  • Senior Management
  • K. Peter Hirth, PhD, CEO
    Kathleen Sereda Glaub, Pres.
    Gideon E Bollag, PhD, SVP, Research
  • Contact Info
  • Plexxikon Inc.
    Phone: (510) 647-4000
    91 Bolivar Dr.
    Berkeley, CA 94710
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register